ArticleNature2026
Prime assembly with linear DNA donors enables large genomic insertions.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Chromatin Modifications Orchestrate DNA Repair Pathway Choice: Epigenetics Strategies for Enhancing CRISPR-Cas9-Mediated Knock-In Efficiency.Cell proliferation · 2026Review
- Article
- Gene editing using large insertions.Nature biotechnology · 2026Article
- Programmable RNA-Guided DNA Recombination: Mechanisms, Engineering, and Applications.Biomedicines · 2026Review
- Large serine recombinase-mediated gene insertion for high-throughput screens: advantages, design principles, and applications.Nucleic acids research · 2026Review
- Advances in prime editing: Molecular innovations, Large-fragment engineering, and AI-driven design.Biodesign research · 2026Review
- Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing.Nature biotechnology · 2026Article
- Donor-complementary prime editing enables precise kilobase and library-compatible DNA insertions.Nature biotechnology · 2026Article
- The use of homology-directed repair in a complex landscape of genome editors.Nature reviews. Molecular cell biology · 2026Article
- Fourth-generation gene editors: Integration-based genome engineering.Molecular therapy. Advances · 2026Review
- A primer on prime: A prime editing update from advances to first-in-human trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Article
- Evolution of Prime Editing: Enhancing Efficiency and Expanding Capacity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy.Frontiers in immunology · 2026Review
Corrections and comments
- Update of
Authors and funding
13 authors.
Bin LiuRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA. liu.13112@osu.edu.ORCID http://orcid.org/0000-0002-3168-8456
Andrew PettiRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0009-0005-8359-8590
Xuntao ZhouRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Haoyang ChengRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0003-3313-9853
Jenny GaoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Matthew YeeRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0001-5354-9820
Youwei QiaoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Yanjun ZhangDepartment of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH, USA.
Lin ZhouDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0003-2581-4345
Scot A WolfeDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-7042-201X
Tingting JiangIcahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0753-2731
Erik J SontheimerRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA. erik.sontheimer@umassmed.edu.ORCID http://orcid.org/0000-0002-0881-0310
Wen XueRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA. wen.xue@umassmed.edu.ORCID http://orcid.org/0000-0002-9797-8042
Funding
Vector Immunology CoreP01HL158506 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Wen Xue · 2021 to 2026
$19.5MDevelop combinatorial non-viral and viral CRISPR delivery for lung diseasesUH3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2021 to 2022
$2.9MIn vivo prime editing for precision cancer mouse modelsR01CA275945 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Wen Xue · 2023 to 2026
$2.5MAdvanced Delivery Platforms for Base Editing In VivoR01GM150273 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ERIK J. SONTHEIMER, Wen Xue · 2023 to 2026
$2.4MDevelopment of a versatile paired prime editing toolkit for CFTR gene correctionR01HL178943 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Tingting Jiang · 2025 to 2026
$1.5MUsing base editing to investigate CFTR polymorphisms in lung diseasesR00HL153940 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JIANG, TINGTING · 2023 to 2025
$747kDeveloping a novel adenine base editor tool for in vivo alpha-1 antitrypsin deficiency gene correction.F30HL176024 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Jenny Gao · 2024 to 2026
$103kNCI NIH HHS R01 CA275945NHLBI NIH HHS F30 HL176024NHLBI NIH HHS P01 HL158506NHLBI NIH HHS R00 HL153940NHLBI NIH HHS R01 HL178943NHLBI NIH HHS UH3 HL147367NIGMS NIH HHS R01 GM150273
Abstract
Targeted insertion of large DNA fragments has promising applications for genome engineering and gene therapy
Indexed as
Genetic EngineeringGenomicsMutagenesis, InsertionalAnimalsDNADNA End-Joining RepairGenomeHumansRecombinational DNA RepairTemplates, GeneticDNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.